High Levels of Folate From Supplements and Fortification Are Not Associated With Increased Risk of Colorectal Cancer

Epidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303-1002, USA.
Gastroenterology (Impact Factor: 13.93). 04/2011; 141(1):98-105, 105.e1. DOI: 10.1053/j.gastro.2011.04.004
Source: PubMed

ABSTRACT Folate intake has been inversely associated with colorectal cancer risk in several prospective epidemiologic studies. However, no study fully assessed the influence of the high levels of folate that are frequently consumed in the United States as a result of mandatory folate fortification, which was fully implemented in 1998, and the recent increase in use of folate-containing supplements. There is evidence that consumption of high levels of folic acid, the form of folate used for fortification and in supplements, has different effects on biochemical pathways than natural folates and might promote carcinogenesis.
We investigated the association between folate intake and colorectal cancer among 43,512 men and 56,011 women in the Cancer Prevention Study II (CPS-II) Nutrition Cohort; 1023 were diagnosed with colorectal cancer between 1999 and 2007, a period entirely after folate fortification began. Cox proportional hazards regression was used to calculate multivariate hazards ratios (RR) and 95% confidence interval (CI).
Intake of high levels of natural folate (RRQ5vsQ1=0.86; 95% CI: 0.70-1.06; P trend=.12) or folic acid (RRQ5vsQ1=0.84; 95% CI: 0.68-1.03; P trend=.06) were not significantly associated with risk of colorectal cancer. Total folate intake was significantly associated with lower risk (RRQ5vsQ1=0.81; 95% CI: 0.66-0.99; P trend=.047).
Intake of high levels of total folate reduces risk of colorectal cancer; there is no evidence that dietary fortification or supplementation with this vitamin increases colorectal cancer risk.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer is the third most common cancer and the third leading cause of cancer death in men and women in the United States. This article provides an overview of colorectal cancer statistics, including the most current data on incidence, survival, and mortality rates and trends. Incidence data were provided by the National Cancer Institute's Surveillance, Epidemiology, and End Results program and the North American Association of Central Cancer Registries. Mortality data were provided by the National Center for Health Statistics. In 2014, an estimated 71,830 men and 65,000 women will be diagnosed with colorectal cancer and 26,270 men and 24,040 women will die of the disease. Greater than one-third of all deaths (29% in men and 43% in women) will occur in individuals aged 80 years and older. There is substantial variation in tumor location by age. For example, 26% of colorectal cancers in women aged younger than 50 years occur in the proximal colon, compared with 56% of cases in women aged 80 years and older. Incidence and death rates are highest in blacks and lowest in Asians/Pacific Islanders; among males during 2006 through 2010, death rates in blacks (29.4 per 100,000 population) were more than double those in Asians/Pacific Islanders (13.1) and 50% higher than those in non-Hispanic whites (19.2). Overall, incidence rates decreased by approximately 3% per year during the past decade (2001-2010). Notably, the largest drops occurred in adults aged 65 and older. For instance, rates for tumors located in the distal colon decreased by more than 5% per year. In contrast, rates increased during this time period among adults younger than 50 years. Colorectal cancer death rates declined by approximately 2% per year during the 1990s and by approximately 3% per year during the past decade. Progress in reducing colorectal cancer death rates can be accelerated by improving access to and use of screening and standard treatment in all populations. CA Cancer J Clin 2014;00:000-000. © 2014 American Cancer Society.
    CA A Cancer Journal for Clinicians 03/2014; DOI:10.3322/caac.21220 · 162.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The U.S. has been reported as the only country experiencing a decline in incidence rates of colorectal cancer (CRC), despite increasing prevalence of CRC major risk factors, including the Western dietary pattern and obesity. This paper presents a hypothesis that improved folate status in the U.S. is the factor that could most likely explain the seemingly contradictory phenomenon, although a momentary increase in CRC incidence rates was observed in the later 1990s with the initiation of nationwide folic acid fortification. To corroborate this hypothesis, time trends in CRC incidence rates and death rates in the U.S. were plotted by age, race, and gender based on data from the Surveillance, Epidemiology, and End Results (SEER); data were analyzed by simultaneously addressing the following four critical factors: (1) a long induction period between improved folate status and potential protection of CRC; (2) a change in the U.S. Food and Drug Administration regulation in 1973 on the dose of folic acid allowed in supplements; (3) differential impacts of 1973 regulatory change and 1990s mandatory fortification by race; and (4) changes in CRC screening over time in the U.S. Although this type of analysis precludes a definitive conclusion, available evidence suggests that the increase in CRC incidence rates in the later 1990s is unlikely due to folic acid fortification and, assuming a time lag of a decade or longer to see a benefit on CRC, folate appears to be one of the most promising factors that could explain the downward trend of CRC incidence rates in the U.S.
    American journal of preventive medicine 03/2014; 46(3 Suppl 1):S65-72. DOI:10.1016/j.amepre.2013.10.025 · 4.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One-carbon metabolism plays an important role in colorectal carcinogenesis. Meta-analyses have suggested protective associations of folate and vitamin B6 intakes with colorectal cancer primarily based on studies in Caucasians, and genetic polymorphisms pertaining to the folate metabolism have been a matter of interest. Less investigated are the roles of methionine synthase (MTR) and thymidylate synthetase (TS) polymorphisms in colorectal carcinogenesis. In a study of 816 cases and 815 community controls in Japan, we investigated associations of dietary intakes of folate, methionine, vitamin B2, vitamin B6, and vitamin B12 with colorectal cancer risk. The associations with MTR 2756A>G, MTRR 66A>G, and TSER repeat polymorphism were examined in 685 cases and 778 controls. Methionine and vitamin B12 intakes were inversely associated with colorectal cancer risk, but the associations were totally confounded by dietary calcium and n-3 fatty acids. The other nutrients showed no association with the risk even without adjustment for calcium and n-3 fatty acids. The TSER 2R allele was dose-dependently associated with an increased risk. The MTR and MTRR polymorphisms were unrelated to colorectal cancer risk. There was no measurable gene-gene or gene-nutrient interaction, but increased risk associated with the TSER 2R allele seemed to be confined to individuals with high folate status. This study does not support protective associations for folate and vitamin B6. The TSER 2R allele may confer an increased risk of colorectal cancer. The role of the TSER polymorphism in colorectal carcinogenesis may differ by ethnicity.
    Asian Pacific journal of cancer prevention: APJCP 11/2013; 14(11):6249-56. DOI:10.7314/APJCP.2013.14.11.6249 · 1.50 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014